Rezolute Reports Phase 3 upLIFT Study Meets Primary Efficacy Endpoint in Tumor Hyperinsulinism
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
Loading...